Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Veterinary autogenous vaccines.

A Hera1, J Bures

  • 1Institute for the State Control of Veterinary Biologicals and Medicaments, Brno, Czech Republic.

Developments in Biologicals
|December 16, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum MicroRNA-196, -200 and -423 Improve Diagnostics and Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.

Physiological research·2025
Same author

ADMET parameters of tacrine and its metabolites confirm unsuitability of Sus scrofa f. domestica model to study tacrine-associated hepatotoxicity.

Chemico-biological interactions·2025
Same author

Gastrointestinal toxicity of systemic oncology immunotherapy.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2022
Same author

Use of electrogastrography in preclinical studies of cholinergic and anticholinergic agents in experimental pigs.

Physiological research·2015
Same author

Anti-Outer membrane protein C antibodies in colorectal neoplasia.

Folia microbiologica·2015
Same author

Preparing Triple-Compound Heterozygous Control Material for Molecular Diagnostics of TPMT Allelic Variants.

Folia biologica·2015
Same journal

Review of Ebola virus infections in domestic animals.

Developments in biologicals·2013
Same journal

Ebola: facing a new transboundary animal disease?

Developments in biologicals·2013
Same journal

Opportunities in diagnostic and vaccine approaches to mitigate potential heartwater spreading and impact on the American mainland.

Developments in biologicals·2013
Same journal

Q fever diagnosis and control in domestic ruminants.

Developments in biologicals·2013
Same journal

Schmallenberg virus.

Developments in biologicals·2013
Same journal

Classical swine fever.

Developments in biologicals·2013
See all related articles

Veterinary autogenous vaccines are widely used but lack harmonized EU regulation, posing risks like contaminant transmission. Harmonized regulations are needed to ensure quality and safety, restricting use to cases without approved alternatives.

Area of Science:

  • Veterinary Medicine
  • Regulatory Science

Background:

  • Autogenous vaccines are veterinary medicinal products prepared from disease-causing agents affecting a specific animal or premises.
  • Their use is prevalent in Central European countries, with a long tradition in the Czech Republic, Hungary, and Slovak Republic.
  • Current regulation is fragmented across EU member states, leading to varying levels of oversight.

Purpose of the Study:

  • To analyze the regulatory landscape of autogenous vaccines in Europe.
  • To identify the risks and benefits associated with their use.
  • To propose a harmonized regulatory approach at the EU level.

Main Methods:

  • Review of existing EU directives and national regulations pertaining to veterinary autogenous vaccines.
  • Analysis of potential risks, including transmission of TSE agents and microbial contaminants.

Related Experiment Videos

  • Examination of the benefits for animal health and welfare when approved alternatives are unavailable.

    • Main Results:

    • Autogenous vaccines are exempt from harmonized EU-level regulation, resulting in inconsistent national control measures.
    • Significant risks include the potential for transmitting serious animal diseases and other contaminants.
    • Benefits are recognized in specific animal health management scenarios, but their use is not without drawbacks.

    Conclusions:

    • Harmonized EU legislation is necessary to address the regulatory inconsistencies and ensure the quality and safety of autogenous vaccines.
    • Regulation should consider both the risks and benefits, restricting use to situations where no authorized alternatives exist.
    • Balanced regulation can prevent trade barriers and support responsible use in animal health and welfare.